Therefore, we evaluated the efficacy of CD8α ALN-1 as an adjuvant in a prime-boost vaccination strategy, using whole-inactivated X47 (H3N2) virus (WIV) as source of viral antigen, to protect against challenge infection with a heterosubtypic H1N1 2009 pandemic (pH1N1) influenza virus, a mouse-adapted derivative from a clinical isolate responsible for the 2009 flu pandemic (Fig. 5a). The gene discussed is CD8A; the disease is infection.